Investor Relations

Press Releases

Date Title and Summary View
May 09, 2016
Cash Expected to Fund Operations through the End of 2017 Clinical Trial Expected to Complete in Fourth Quarter 2016 and Resubmission Planned for First Half 2017 PRINCETON, N.J., May 09, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical
Apr 15, 2016
PRINCETON, N.J. , April 15, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products announced today that Dr.
Mar 30, 2016

Presentation Scheduled on Wednesday, April 13, 2016 at 4:20 PM Eastern Time

Mar 09, 2016

Cash Expected to Fund Operations Through the End of 2017

Mar 03, 2016

Presentation Scheduled on Monday, March 14, 2016 at 7:30 AM Pacific Time

Feb 24, 2016

Andrew Schiff, M.D. to Step Down From the Board

Feb 16, 2016

Presentation Scheduled on Tuesday, February 23, 2016 at 8:00 AM ET 

Feb 04, 2016
PRINCETON, N.J., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that the underwriters of its previously announced
Jan 22, 2016
PRINCETON, N.J., Jan. 22, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced the pricing of its underwritten public offering
Jan 21, 2016
PRINCETON, N.J., Jan. 21, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that it intends to offer and sell $30 million of